MG
CBIO

Michael Gelband’s Crescent Biopharma CBIO Stock Holding History

Michael Gelband’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-357
Closed -$107K – 1685
2024
Q1 		$107K Sell
357
-601
-63% -$180K ﹤0.01% 1408
2023
Q4 		$226K Buy
+958
New +$149K ﹤0.01% 1254
2022
Q2 		– Sell
-107
Closed -$12K – 2121
2022
Q1 		$12K Sell
107
-186
-63% -$21.8K ﹤0.01% 2114
2021
Q4 		$42K Buy
293
+69
+31% +$12.5K ﹤0.01% 2050
2021
Q3 		$49K Sell
224
-388
-63% -$82.2K ﹤0.01% 1972
2021
Q2 		$142K Buy
612
+441
+258% +$112K ﹤0.01% 2073
2021
Q1 		$52K Sell
171
-380
-69% -$136K ﹤0.01% 2025
2020
Q4 		$207K Buy
+551
New +$193K ﹤0.01% 1714

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's CBIO Position: Q2 2024 in Review

Michael Gelband sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 357 shares — an estimated $107K sold.

Michael Gelband first reported a position in CBIO in Q4 2020 and held it in 8 quarters. The position peaked at $226K in Q4 2023. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Michael Gelband reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Michael Gelband sold 357 Crescent Biopharma shares in Q2 2024, an estimated $107K.
  • Michael Gelband first reported a position in Crescent Biopharma in Q4 2020 and held it in 8 quarters.
  • Michael Gelband's Crescent Biopharma position peaked at $226K in Q4 2023.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.